A groundbreaking study has demonstrated the life-saving benefits and cost-effectiveness of screening newborns for a severe muscle-wasting disease. The Mirror is advocating for the implementation of a simple £5 blood test for spinal muscular atrophy (SMA) across the NHS, supported by research from Oxford University. According to findings published in the Lancet medical journal, 507 babies have been born with SMA in the UK since 2019, highlighting the urgent need for early detection and treatment.
In the absence of newborn screening for SMA in the UK, infants with the most severe Type 1 form were diagnosed at an average age of six months, leading to significant health challenges. Comparatively, in southern Belgium where SMA screening is conducted at birth, all affected babies survived without requiring long-term medical interventions.
The study, led by Professor Laurent Servais, emphasized the detrimental impact of the UK’s decision not to implement an SMA screening program, resulting in poorer outcomes for affected children. By analyzing data from different regions, researchers highlighted the benefits of early detection and treatment, underscoring the necessity of nationwide screening initiatives.
Furthermore, the study revealed stark differences in the financial burden of supporting SMA babies in the UK compared to countries with screening programs. The Mirror has been campaigning for the inclusion of SMA screening in the NHS newborn testing regimen to prevent unnecessary suffering among children.
The story of Ezra Thorman, a young SMA patient who faced challenges due to a delayed diagnosis, shed light on the importance of early intervention. Pharmaceutical company Novartis estimates that a significant number of UK infants are left with disabilities due to late diagnosis of SMA.
SMA is a genetic disorder affecting the production of a crucial protein that sustains nerve cell health. While there are effective treatments available, including gene therapies, their impact diminishes if administered late in the disease progression.
Despite global trends in SMA screening, the UK lags behind, prompting calls for immediate action to prevent further tragedies among infants affected by the condition. The commitment of healthcare authorities to explore screening initiatives offers hope for improved outcomes for SMA patients in the future.